Preventive Effects of Sitagliptin on Endothelial Dysfunction Induced by Forearm Ischemia-Reperfusion Injury Model

NCT02406950 Phase 3 UNKNOWN

Over the years, numbers of cardioprotective drugs have been evaluated to attenuate lethal ischemia-reperfusion (IR) injuries. There is little study whether sitagliptin protects against endothelial dysfunction induced by IR injury in humans.

Details

Lead sponsor	Kyunghee University Medical Center
Phase	Phase 3
Status	UNKNOWN
Enrolment	10
Start date	2015-02
Completion	2015-08

Conditions

• Healthy

Interventions

• Sitagliptin

Primary outcomes

• The difference of FMD [brachial artery endothelium-dependent flow-mediated dilatation] after IR injury (brachial FMD before and after IR injury will be assessed) — 2 hours after study drug treatment

Countries

South Korea